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Background: Limited data exist on the efficacy and safety of home intravenous antibiotic (IV-
AB) therapy for pulmonary infection specifically in children with cystic fibrosis (CF).
Methods: We report on the outcome of IV-AB in the home vs hospital setting based on retro-
spective single centre patient data from 1999 to 2004 (age >5 and <18 years). Treatment loca-
tion was chosen based on estimation of competence, adherence, social background and
patient preference. Primary outcome parameter was change in FEV1. Secondary outcome
parameters were weight and IgG as well as occurrence of complications.
Results: One hundred and thirty-one treatment observations (TOs) were analysed for 47
patients. Mean age was 13.32 (2.9) years and mean FEV1 65 (19) % predicted. Fifty-four
(41%) TO’s were home and 77 (59%) were hospital treatments. Percent change in FEV1 and
weight gain was comparable in the 2 settings. Complications were rare in both groups.
Conclusion: The outcome of IV-AB therapy for lung infection in children with CF was not infe-
rior in the home compared to the hospital setting. In our centre, home IV-AB treatment is
a valuable treatment option for children with CF.
ª 2008 Elsevier Ltd. All rights reserved., treatment observation; IV-
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Cystic fibrosis (CF) is an autosomal recessive disease caused
by mutations in the CFTR gene, a gene coding for a trans-
membrane epithelial chloride channel. Formost patients the
cardinal disease feature is chronic bacterial lung infection
with organisms like Staphylococcus aureus, Haemophilus.
IV treatment at home in paediatric cystic fibrosis 245influenzae and e with increasing age e non-fermenting
Gram negatives like Pseudomonas aeruginosa. This relent-
less bacterial infection leads to chronic neutrophilic
inflammation and progressive lung damage ultimately
leading to respiratory failure.1,2
Frequent and long duration antibiotic (AB) treatment via
different routes is the cornerstone in slowing down
progression of lung disease. While oral and inhaled antibi-
otics provide sufficient treatment for many CF lung infec-
tions, intravenous AB (IV-AB) is often needed especially in
the treatment of P. aeruginosa (Pa) infection. Courses of at
least 2 weeks are given to treat exacerbation of respiratory
infection. For some patients elective 3 monthly IV-AB
treatment may have advantages over treating exacerba-
tions only.3,4 Both regimens may involve 4 treatments
a year of 14 days duration each. Therefore home IV-AB
therapy is being used in many centres: it is less disruptive
for the patient’s social life and has economic advantages.5
Insufficient medication compliance and low adherence with
physiotherapy as well as lack of rest are possible pitfalls
and may reduce the efficacy of home therapy. In several
countries the experience with and outcome of home IV-AB
therapy are being reported since the 1980s, most publica-
tions concerning adults.6e10 Over the last 15 years several
studies compared the efficacy and safety of home vs
hospital therapy with very different study designs11e19 and
only few studies selectively showing paediatric data.
Since home therapy for IV-AB has an important place in our
paediatric CF centre, we wanted to evaluate if the outcome
of IV-AB therapy in the home setting was equivalent to
hospital treatment for paediatric and adolescent CF patients.
Material and methods
Study population
Charts of CF patients followed in our centre and treated
with IV-AB for 14 days for pulmonary infection between
January 1st 1999 and December 31st 2004 were included in
this retrospective analysis provided their age was between
5 and 18 years at the time of treatment. A ‘pulmonary
exacerbation’ was defined as: worsening of respiratory
infection warranting the institution of IV antibiotic therapy.
The diagnosis of CF was made by sweat testing and geno-
type in patients with typical clinical signs and symptoms.
Exclusion criteria were: IV-AB therapy longer than 14
days and/or for reason other than pulmonary infection (e.g.
infection of indwelling catheter), cognitive impairment
(leading to inability to perform lung function) or other
medical conditions possibly interfering with treatment
outcome.
Patients were selected using the computerized database
of the CF reference of the University Hospital Data of
Leuven, Belgium. Data were collected from the medical
records and the database. The study was approved by the
local ethical committee.
Home vs hospital based therapy
Every patient started ‘in-hospital’ treatment during 3 days,
after which ‘home therapy’ was continued at home. For‘hospital treatment’ the full treatment was received in our
hospital. Since these data refer to a retrospective analysis
and not a prospective study, patients were not ‘selected’
nor ‘randomized’ to either treatment location. In our clinic
if a patient needs IV therapy, the request for home therapy
usually comes from the patient or parent. The team will
then consider this question and evaluate the following
items: (1) age of the patients (never home IV below age 5
and usually not before age 12), (2) does the medical
condition of the patient allow safe home therapy (disease
severity, other factors like antibiotic allergies or co-
morbidities), (3) has the patient previous experience with
IV in hospital (we never perform the first IV treatment at
home), (4) how are the social background and support
(since burden of therapy is high for home therapy), (5) are
the parents and patient skilled enough to perform the
medical acts needed, and (6) how do we estimate adher-
ence with therapy in this family (medication,
physiotherapy).
Final decision about treatment location is based
primarily on estimation of competence and treatment
adherence (as was carefully judged by the treating multi-
disciplinary team). Previous IV therapy and request for
home therapy by patient or parents are important factors in
this decision. Allocation to home therapy was therefore not
based on strict criteria. It reflects our previous and current
clinical practice.
For both groups antibiotics combination was chosen
based on recent sputum culture and antibiotic sensitivity.
Most patients were treated with piperacillinetazobactam,
ceftazidim or meropenem in combination with tobramycin.
During hospitalisation the multidisciplinary CF team was
involved in the care. Chest physiotherapy was provided
twice daily by the CF physiotherapist. In the home group,
the parents (or for older children the patient) were
instructed to prepare and administer IV medication. Phys-
iotherapy was continued as routine (independently or with
the home physiotherapist with a frequency of at twice daily
chest physiotherapy during IV treatment). At the end of
therapy, home IV patients were evaluated in clinic with
lung function and blood biochemistry.
During the years of the study no home care support was
provided by the CF nurse specialist. Patients had, however,
the possibility of contacting the medical team for questions
and practical issues throughout the therapy.
Baseline parameters
The following parameters were noted:
(1) age, gender, and experience with IV therapy (4 cate-
gories: 1st, 2nd, 3rd, 4th or more therapy),
(2) Lung function expressed in absolute values and % pre-
dicted according to Knudson20 (measured with Master
screen spirometry Jaeger Paed according to ATS
guidelines).21 If available lung function after a bron-
chodilator was taken (as a rule lung function is per-
formed before and after salbutamol. Exceptionally,
only prebronchodilator lung function is performed if
reversibility is absent repeatedly).
(3) weight, BMI and BMI z-score,22
(4) IgG in mg/dl as measure of lung infection,
Table 1 Baseline characteristics of the home and hospital
treatment observations.
Home
(nZ 54)
Hospital
(nZ 77)
p-
Value
Age (years) mean (SD) 13.54
(2.6)
13.17
(3.1)
0.11
Weight (kg) mean (SD) 42.7
(14.6)
40.7
(12.9)
0.98
BMI z-score mean (SD) 1.1
(1.2)
1.2
(1.4)
0.76
FEV1 (l/s) mean (SD) 1.62
(0.64)
1.69
(0.73)
0.14
FEV1 % predicted mean (SD) 63
(19)
66
(20)
0.82
IgG (mg%) mean (SD) 1688
(549)
1430
(473)
0.25
Male/female mean (SD) 9/45 44/33 <0.001
Indwelling catheter yes/no 32/22 47/30 0.84
R/indication: Chronic Pa 37 57 0.49
R/indication: Int. Pa 1 4 0.33
R/indication: other 12 11 0.24
R/indication: B. cepacia 4 5 0.84
246 M. Proesmans et al.(5) infecting organism (chronic or intermittent infection with
P.aeruginosadefinedaccording totheEuropeanconsensus
definition,23 infection with Burkholderia cepacia, infec-
tion with other microorganisms (S. aureus, Alcaligenes
xylosoxidans, Stenotrophomonas maltophilia)),
(6) indwelling catheter yes/no.
Outcome parameters
Primary outcome parameter was improvement in FEV1
(expressed as the absolute difference in l/s), FEV1 %
predicted after e before and ‘FEV1, percent change
calculated as absolute change in FEV1/(FEV1 at
start) 100’. Secondary outcome parameters were weight
gain (weight at end of therapy e weight begin therapy and
change in BMI and BMI z-score), change in IgG (absolute
change and % change) and complications during IV therapy
(catheter infection, allergic reaction, hemoptysis,
pneumothorax).
Data selection and statistical analysis
For variables with a normal distribution, an independent
sample Student’s t-test was used for continuously scaled
variables. A Chi-square was selected for comparison of
nominal variables. All statistical procedures were con-
ducted using SPSSwin version 11.
Since data represented treatment episodes and not
patients, patients with 4 IV therapies yearly represent
a large number of treatment episodes possibly distorting
the data. Therefore, only the first treatment of every year
was included in the analysis. To exclude the variable of
‘experience with IV therapy’ only treatments of patients
with at least 4 previous IV treatments (home or hospital)
were selected.
Results
From 96 patients in follow-up aged 5e18 years, 131 TO
(representing 47 patients) were included in the analysis (13
patients were included once, 10 twice, 9 three times, 7 four
times, 5 five times and 3 six times). Fifty-four TO’s (41%)
were performed at home and 77 (59%) in hospital; 53 (40%)
episodes occurred in male and 78 (60%) episodes in female
patients. For 79 (60%) treatments an indwelling catheter
was in place.
Ninety-four TO’s were in-patients with chronic Pa
infection (72%), 5 (4%) in-patients with intermittent Pa, 9
(7%) in-patients with Bc infection and 23 (17%) in-patients
with other infecting organisms (S. aureus, S. maltophilia,
A. xylosoxidans, etc). The comparison of the baseline
characteristics and the infecting organism for the home and
hospital TO are found in Table 1.
Outcome of IV therapy
Primary outcome parameter
Lung function improvement was comparable in the home
and the hospital setting. This was the case for FEV1 in
absolute values (0.21 l/s 0.25 in home and 0.23 l/s 0.4
in hospital; pZ 0.71), improvement of FEV1 percentpredicted (7.4% 9.8 and 8.0% 13.3; pZ 0.80) and for
percent change in FEV1 (17 27 and 17 24; pZ 0.94).
Secondary outcome parameters
Mean weight gain was 0.7 kg 1.0 in the home setting and
0.4 kg 1.4 for the hospital setting (pZ 0.14). Change in
BMI (0.33 0.46 vs 0.17 0.59; pZ 0.08), change in BMI
z-score (0.20 0.28 vs 0.12 0.46; pZ 0.30) and relative
weight change (2.1 3.0 vs 1.14 3.80; pZ 0.12) were
also comparable in the 2 settings.
IgG decrease was larger in the hospital setting
(69 173 mg/dl vs 21 167 mg/dl, respectively),
however, this was not statistically significant (pZ 0.15).
Percent change in IgG did neither differ significantly
(0.1 0.09 home vs 0.03 0.12 hospital; pZ 0.30).
The number of complications was low and did not differ
between the 2 settings (pZ 0.66): 2 allergic reactions to
antibiotics in each setting, 1 pneumothorax after home IV-
AB therapy and 1 case of hemoptysis in the hospital setting.
Discussion
IV-AB therapy has an important place in the treatment of CF
lung infection especially in patients chronically colonized
with Pa. Our data reported here are encouraging and do not
show inferior outcome of IV therapy administered by
parents at home compared to hospital treatment in our
centre, even though little support is currently given in the
home setting. We are, however, aware, that these results
reflect our centre practice and may not be generalised.
A recent US retrospective chart study by Nazer et al.19
(see Table 2 for literature overview) reported better
outcome after hospital compared to home therapy in CF
patients (upper age 20 years) treated for acute pulmonary
exacerbation. Percent change in FEV1 was 23% in the home
and 39% in the hospital group (compared to 17% in each of
Table 2 Literature overview on home versus hospital IV therapy in cystic fibrosis.
First author Year
of
publi
cation
Country Study design Age
(years)
range
mean
Allocation of
groups
Baseline FEV1
(mean)
Number utcome Additional
information
Strandvik 1992 Sweden Retrospective 4e67 Distance from
hospital
45% For home 41 Courses in
hospital,
51 at home
F, Pa counts,
lood gas:
omparable
Exacerbation of
chronic Pa groups
not comparable at
start: patients with
hospital treatments
younger and less ill
21 Patient’s
choice
64% For hospital
group
Pond 1993 UK Retrospective 17e29 Compliance 40% 100 Courses,
50 patients
(each patient
his own
control)
F, IgG, CRP,
-ray score, weight:
omparable WBC
ecreased more in
ospital
Exacerbation of
chronic Pa infection22 Competence
Bosworth 1997 US, Utah Retrospective 7e31 Financial,
competence,
social support
40% For home
and 46% for
hospital group
32 Courses in
hospital,
19 at home
EV1 % change: 23%
hospital vs 14%
t home
Selection of
comparable patients18.8 For
home
and 17.5
for
hospital
group
Wolter 1997 Australia Prospective,
randomized (2
factor mixed)
19e41 Randomized
(second
treatment
allocation in
the other
group)
41% For home
and 44% for
hospital group
31 Courses
randomized
eight, 12 walk
est, sputum, oxygen
at, LF: comparable;
OL better at home
Only 31 of 114
courses randomized22
Riethmueller 2002 Germany Prospective
open
Range? ? 55 For home
and 66% for
hospital group
58 Courses eight, LF, Pa counts,
fection parameters:
omparable
Only elective IV-AB
therapyfor chronic
Pa; use of
intermate infusion
pump
16 In home
and 15 in
hospital
group
Thornton 2004 UK Retrospective >16 Ultimately
patients
choice;
competence,
clinic picture
52% 454 Courses Of patients with
ecrease in FEV1 over
year 2%: 42.6%
atients with home and
2.7% with hospital
herapy
Length of individual
courses ranged from
3 to 172 days
2005 26
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248 M. Proesmans et al.our groups). Decision on treatment location was based on
patient and caregiver preferences as well as available
resources. Differences in FEV1 increase were more
pronounced for patients with severe lung disease. The
mean patient age in the above US study was comparable to
our data, however, the mean FEV1 at start of therapy was
more than 10% lower.
Another retrospective US study by Bosworth and Niel-
son15 also reported superiority of hospital based therapy
with 28% improvement in FEV1 after hospital but only 11% at
home. Data only concerned patients chronically infected
with Pa with a mean age of 18 years and a mean FEV1
% predicted around 45%. Of the 149 hospital and 95 home
treatments only 32 and 27 were analysed to have compa-
rable groups for age and LF. In the retrospective 1 year
study of Thornton13 success of IV-AB therapy in adult CF
patients is analysed with a very different study design:
effect of therapy is evaluated after a period of 1 year and
home therapy is defined as receiving at least 60% of therapy
in the home setting. Treatment proved to be effective
(defined as decline in FEV1 of less than 2% over 1 year) in
59% of patients in the hospital vs only in 43% of patients in
the home therapy group. Mean number of IV courses per
year was 4 (range 1e9) and overall 88% of patients were Pa
colonized. As in our study, more females were represented
in the home group in this study.13 Outcome of home therapy
was better for females compared to males (no gender
difference in our study: data not shown). The larger
proportion of females in the home treatment observation
group most likely reflects their gender disadvantage in CF
and therefore an increased need for IV therapy.24 Another
factor may be that girls are believed to be more compliant
and are more keen to take on their therapy at home.
Three other European studies10e12 support the use of
home IV-AB therapy, 2 of them including mainly adults.12,10 In
the recent openprospectiveGerman study11 onelective IV-AB
therapy in paediatric and adolescent CF patients (mean age
15e16 years) the 2 settings proved to be similarly effective
for lung function, weight and inflammatory markers.
A disadvantage of a retrospective study is that certain
parameters cannot be retrieved (for example, factors that
guide the decision for home therapy, patient satisfaction,
etc); moreover since patients are allocated and not
randomized (and patient preference plays a role in choice of
treatment location), groups are not always comparable at
baseline. Althoughwedid not register number of IV therapies
needed per year, we may expect this value will be higher in
the home therapy group. Especially patient with high
therapy burdenwill prefer the homeover the hospital setting
mainly for QOL reasons.We are aware of the limitation of our
study in this regard (no strict allocation to home or hospital
therapy, no compliance monitoring, no standardisation of
home physiotherapy, no QOL data), however, these data
reflect the real life situation. Some patients are unable/
unwilling to perform home therapy; others are advised
against home therapy if the prescribed treatment is not
followed (for example, chest physiotherapy). Data specifi-
cally on physiotherapy (frequency, type, with physiothera-
pist or self-managed) were not registered and the impact of
these variables could unfortunately not be analysed. In one
adult study patients were prospectively randomized for
home or hospital treatment.25 Although this design has
IV treatment at home in paediatric cystic fibrosis 249theoretical advantages, only 31 of the 114 treatments
episodes were included in the study because of patients
refusal to be randomized. As a consequence, patients
included in the study may not be representative for daily
centre practice. The abovementioned study of Riethmueller
et al. was also planned as a prospective randomized study
but was made open since adolescent patients refused to be
randomized suggesting this design may neither not be real-
istic nor ideal for comparing home and hospital treatment.11
The different results between some European and US
studies may not only be explained by differences in study
design and disease severity. The aspect of selecting and
preparing patients for home therapy may be under-
estimated as an important factor. In our centre, the deci-
sion is not only guided by the patient’s preference but also
by the team’s evaluation of the compliance with therapy,
social support as well as parental technical skills. Factors
like distance from hospital and available resources are
hardly involved. Many patients have access to their usual
physiotherapist for support of airway clearance.
We did not use the parameter ‘time to next pulmonary’
exacerbation in this analysis. Although an important
measure in CF studies, we feel that in this retrospective
study set-up where patients are not randomized, need for
IV therapy is most likely higher in the home group. There-
fore, time to next exacerbation would rather reflect
disease severity than success of therapy.
Our study did not address the issue of cost neither the
aspect of QOL but other studies have reported on these
aspects.26 It is no surprise that home therapy has lower
health-related cost.5
Home therapy for CF lung disease is a reality in many CF
centres. It may be better to adopt a ‘non-inferiority’ trial
design (provided the patient’s competence and preference
are taken into consideration) rather than to test the
hypothesis that hospital IV therapy is necessarily better. The
aim of our study was therefore ‘a real life evaluation’ of our
daily practice as a test of quality control and not
a prospective comparative study. The outcome of home IV-
AB therapy in the treatment of lung infection in children and
adolescents with cystic fibrosis was not inferior to hospital
therapy when looking at lung function, weight and total IgG
as outcome parameters. Selecting and preparing patients for
home therapy may be an important factor for success.
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